Proteogenomic Analysis of Surgically Resected Lung Adenocarcinoma.

Autor:	Sharpnack MF; Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio., Ranbaduge N; Department of Chemistry, The Ohio State University, Columbus, Ohio., Srivastava A; Department of Computer Science and Engineering, The Ohio State University, Columbus, Ohio., Cerciello F; Department of Oncology, University Hospital Zurich, Zürich, Switzerland., Codreanu SG; Department of Chemistry, Vanderbilt University, Nashville, Tennessee., Liebler DC; Department of Biochemistry, Vanderbilt University, Nashville, Tennessee., Mascaux C; Department of Multidisciplinary Oncology and Therapeutic Innovations, Assistance Publique des Hôpitaux de Marseille, France; Aix-Marseille University, Marseille, France., Miles WO; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts., Morris R; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts., McDermott JE; Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA., Sharpnack JL; Department of Statistics, University of California, Davis, California., Amann J; Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio., Maher CA; Department of Medicine, Washington University in St. Louis, St. Louis, Missouri., Machiraju R; Department of Computer Science and Engineering, The Ohio State University, Columbus, Ohio., Wysocki VH; Department of Chemistry, The Ohio State University, Columbus, Ohio., Govindan R; Department of Medicine, Washington University in St. Louis, St. Louis, Missouri., Mallick P; Department of Radiology, Stanford University, Palo Alto, California., Coombes KR; Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio., Huang K; Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio., Carbone DP; Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. Electronic address: david.carbone@osumc.edu.
Jazyk:	angličtina
Zdroj:	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2018 Oct; Vol. 13 (10), pp. 1519-1529. Date of Electronic Publication: 2018 Jul 11.
DOI:	10.1016/j.jtho.2018.06.025
Abstrakt:	Introduction: Despite apparently complete surgical resection, approximately half of resected early-stage lung cancer patients relapse and die of their disease. Adjuvant chemotherapy reduces this risk by only 5% to 8%. Thus, there is a need for better identifying who benefits from adjuvant therapy, the drivers of relapse, and novel targets in this setting. Methods: RNA sequencing and liquid chromatography/liquid chromatography-mass spectrometry proteomics data were generated from 51 surgically resected non-small cell lung tumors with known recurrence status. Results: We present a rationale and framework for the incorporation of high-content RNA and protein measurements into integrative biomarkers and show the potential of this approach for predicting risk of recurrence in a group of lung adenocarcinomas. In addition, we characterize the relationship between mRNA and protein measurements in lung adenocarcinoma and show that it is outcome specific. Conclusions: Our results suggest that mRNA and protein data possess independent biological and clinical importance, which can be leveraged to create higher-powered expression biomarkers. (Copyright © 2018 International Association for the Study of Lung Cancer. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu